Sections News

Invitation to apply to MSD "IBD Academy" 2016

This programme, which has been running for 8 years, allows trainees with a particular interest in IBD to undergo training in important professional skills at a weekend course, and subsequent full sponsorship to attend the 12th annual European Crohn’s and Colitis Organisation (ECCO) congress, which is from February 15th to 18th 2017 in Barcelona.

The weekend course will be held in London on November 19th/20th 2016, and has the overall objective of improving the quality of care provided to patients. It will cover subjects such as workforce planning, NHS structure, service development, setting up clinical research, the consultant’s role in the new NHS and the challenges of being a new consultant.

Completed applications should be submitted electronically to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Application Deadline: July 24th 2016.

Invitation to apply to MSD "IBD Academy" 2016

This programme, which has been running for 8 years, allows trainees with a particular interest in IBD to undergo training in important professional skills at a weekend course, and subsequent full sponsorship to attend the 12th annual European Crohn’s and Colitis Organisation (ECCO) congress, which is from February 15th to 18th 2017 in Barcelona.

The weekend course will be held in London on November 19th/20th 2016, and has the overall objective of improving the quality of care provided to patients. It will cover subjects such as workforce planning, NHS structure, service development, setting up clinical research, the consultant’s role in the new NHS and the challenges of being a new consultant.

Completed applications should be submitted electronically to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Application Deadline: July 24th 2016.

BSG Guidance on the Use of Biosimilar Infliximab CT-P13 in IBD

February 2016

Introduction: Dr AB Hawthorne, Chair BSG IBD Section Committee

The infliximab biosimilar CT-P13 (Remsima or Inflectra) received marketing authorisation in June 2013.The drug is now widely used in the treatment of inflammatory bowel disease. There is sufficient data from observational studies to show that safety and clinical efficacy of CT-P13 are comparable to the originator drug, with similar immunogenicity.

Recommendations

  1. Infliximab must be prescribed by brand name (ie Remicade, Remsima or Inflectra) and not by International Non-proprietary Name (INN).
  2. For patients starting infliximab: Remicade, Remsima or Inflectra can be prescribed, taking into account the evidence showing similar clinical effectiveness. There is evidence that monitoring of patients, including measurement of drug and anti-drug antibody levels, is no different for the biosimilar drugs compared to Remicade. The choice of preparation should take into account the cost of the drug and its administration.
  3. There is sufficient evidence to recommend that patients who are in a stable clinical response or remission on Remicade therapy can be switched to Remsima or Inflectra at the same dose and dose interval. This should be done after discussion with individual patients, with explanation of the reason for switching (which is usually on the grounds of benefit to the overall service by reduction in costs of the drug and its administration).
  4. Automatic substitution, (dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level without consulting the prescriber), is not appropriate.
  5. Pharmacovigilance is essential for any new biological medicine, and patients prescribed Remsima or Inflectra should be followed for safety, in a registry such as the UK National IBD Registry.

This document replaces the previous BSG guidance on Biosimilar drugs - IBD Section Statement on Biosimilar drugs (2014) (View here)

Fourth report of the biological therapy element of the UK IBD audit

Latest UK IBD audit report shows further improvement for patients following treatment with biological therapies

The UK inflammatory bowel disease (IBD) clinical audit report reveals today that the majority of patients (80% adult and 77% paediatric) with Crohn's disease saw an improvement following biological therapies

This is the fourth report of the biological therapy element of the UK IBD audit. The purpose of this audit is to measure the efficacy, safety and appropriate use of the biological therapies infliximab and adalimumab, also known as anti-TNFα drugs, in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.

The data presented in the reports demonstrate that biological therapies for IBD are effective and relatively safe treatments. Patterns of use are changing, with earlier use in patients with less severe disease. It is likely that this reflects more appropriate prescribing as physicians become more familiar with these drugs.

National and executive summary versions of both adult and paediatric reports are available on the Royal College of Physicians' website:

Biosimilar Medicines: all you need to know

Professor Chris Probert, Chair BSG IBD Committee

The announcement by NICE that anti-TNFs may be used, within licence, for patients with ulcerative colitis has coincided with the launch of two biosimilar infliximabs in the UK.

We (BSG) are arranging an educational meeting in conjunction with representatives from the Association of the British Pharmaceutical Industry Biological Medicines Access Group (ABPI BMAG), Hospira and Napp. Our goal is to deliver an educational event with talks from all interested parties as well as from MHRA and NICE. The meetings are on 9th (London) and 16th (Manchester) June and commence at 14:00.

Page 1 of 3